FDA granted accelerated approval for Etcamah combination therapy after trial results were presented at ASCO.

The entities involved

• AstraZeneca →

  British-Swedish pharmaceutical company

  • AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Mon 11:04
  • Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.Sat 18:52
• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Related events

• Daiichi Sankyo and AstraZeneca partnered on the development of the Enhertu drug, which was tested in Etcamah trials combined with Ibrance as a UK drugmaker.Sep 14
• AstraZeneca and Sachi are collaborating on trials for Non-Small Cell Lung Cancer (NSCLC), with the results of the Saffron trial potentially leading to U.S. approval.Aug 17
• Iovance Biotherapeutics received FDA approval for its therapy, and the company is listed on Nasdaq.Jun 20